Accuray (ARAY) said Monday that it received approval from the Chinese National Medical Products Administration for its Radixact SynC and CyberKnife S7 System.
Radixact SynC is a radiation therapy system designed to deliver precise and personalized treatment to patients with cancer and CyberKnife S7 is a robotic radiosurgery device for treating cancerous and benign tumors, the company said.
Shares of the company were up 2.1% in recent trading.
Price: 2.19, Change: +0.04, Percent Change: +2.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.